The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer

Basit Öğe Kaydı
dc.authoridEralp, Yesim/0000-0001-9603-4755;
dc.authorwosidUygun, Kazim/AFL-7917-2022
dc.authorwosidAydiner, Adnan/AAU-4591-2020
dc.authorwosidEralp, Yesim/AAD-7194-2020
dc.authorwosidTas, Faruk/AAF-8751-2019
dc.authorwosidUygun, Kazim/AAG-7880-2022
dc.authorwosidSaip, pınar/AAT-1500-2020
dc.contributor.authorKaragol, Hakan
dc.contributor.authorSaip, Pinar
dc.contributor.authorUygun, Kazim
dc.contributor.authorCaloglu, Murat
dc.contributor.authorEralp, Yesim
dc.contributor.authorTas, Faruk
dc.contributor.authorAydiner, Adnan
dc.date.accessioned2024-06-12T11:11:51Z
dc.date.available2024-06-12T11:11:51Z
dc.date.issued2007
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground: Activity of tamoxifen as a salvage therapy in patients with advanced epithelial ovarian cancer was evaluated by a number of studies. In this study, we evaluated efficacy of tamoxifen in our patients with platinum-resistant epithelial ovarian carcinoma. Patients and Methods: A retrospective analysis was conducted of patients who received tamoxifen at a dose 20 mg twice daily for the treatment of advanced epithelial ovarian cancer. Results: Twenty-nine eligible patients were included to the study. There were 1 (3%) complete response, 2 (7%) partial response, 6 (21%) stable disease, and 20 (69%) progressive disease. All patients were progressed after initiation of tamoxifen. Median progression-free survival was 4 mo (95% CI: 2.98-5.02). Disease progression of 19 (65%) patients were shown within the first 6 mo after initiation of tamoxifen. Progression-free survival was between 6 and 12 mo for 7 (24%) patients and >= 12 mo for 3 (10%) patients. The median survival after initiation of tamoxifen was 15 mo (95% CI: 7.2-22.8). No toxicity attributable to tamoxifen was seen in any of the patients. The only independent prognostic factor that had a significant predictive value for progression-free survival was the response to tamoxifen treatment (p = 0.043, hazard ratio: 0.12, 95% CI: 0.01-0.94). Conclusion: Considering minimal side effects and ability to cause objective responses, there is a place for tamoxifen in treatment of patients with platinum-resistant ovarian cancer. A phase III trial is required to confirm the value of the drug in patients presenting these clinical settings.en_US
dc.identifier.doi10.1007/BF02685901
dc.identifier.endpage43en_US
dc.identifier.issn1357-0560
dc.identifier.issue1en_US
dc.identifier.pmid17673810en_US
dc.identifier.scopus2-s2.0-34548756047en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage39en_US
dc.identifier.urihttps://doi.org/10.1007/BF02685901
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22956
dc.identifier.volume24en_US
dc.identifier.wosWOS:000246767100005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherHumana Press Incen_US
dc.relation.ispartofMedical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOvarian Canceren_US
dc.subjectTamoxifenen_US
dc.subjectCell-Linesen_US
dc.subjectCarcinomaen_US
dc.subjectExpressionen_US
dc.subjectCisplatinen_US
dc.subjectReceptoren_US
dc.titleThe efficacy of tamoxifen in patients with advanced epithelial ovarian canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu